Tyroservatide therapy for tumor growth, invasion and metastasis of Lewis lung carcinoma and human lung carcinoma A549.
The tripeptide tyroservatide (tyrosyl-seryl-valine, p-Tyr-Ser-Val-NH(2), YSV) has been shown to have anti-tumor effects on experimental hepatocarcinoma. The study was conducted to evaluate the therapeutic effects of YSV on tumor growth, invasion and metastasis of lung cancers. Anti-tumor and anti-metastatic effects of YSV were evaluated in three experimental systems. In C57BL/6 mice, a spontaneous metastasis model of Lewis lung cancer was used to study the anti-tumor and anti-metastasis effects of YSV. A549 human lung carcinoma was used to create an orthotopic model in nude mice to investigate the anti-metastasis effect of YSV. Finally, an in vitro model using the B16F10 melanoma cell line was selected to observe the effect of YSV on adhesion and invasion, and to use immunocytochemistry to assay the expression of ICAM-1. YSV inhibited subcutaneous tumor growth of Lewis lung carcinoma (p < 0.05) and markedly decreased lung metastases in the spontaneous metastasis model of Lewis lung cancer and the orthotopic model of A549 human lung carcinoma. In vitro, YSV reduced adhesion and invasion as well as the expression of ICAM-1 in tumor cells. YSV was able to inhibit tumor growth and metastasis in lung cancer.